Intervention
Datopotamab deruxtecan
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 11 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
11 shownPREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseNCT07069595 · 2026-02-26
RECRUITINGA Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)NCT06822543 · 2025-09-12
RECRUITINGPhase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesNCT05866432 · 2023-07-01
RECRUITINGI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01
RECRUITINGDatopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain MetastasesNCT06676917 · 2025-06-01
WITHDRAWNPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29
ACTIVE_NOT_RECRUITINGPhase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerNCT04612751 · 2021-02-02
ACTIVE_NOT_RECRUITINGDatopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)NCT04526691 · 2020-09-15
ACTIVE_NOT_RECRUITINGPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NCT03944772 · 2019-06-25
ACTIVE_NOT_RECRUITINGA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102 · 2018-12-21
ACTIVE_NOT_RECRUITINGMedical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsNCT06279728
APPROVED_FOR_MARKETINGCommon conditions
Advanced or Metastatic NSCLC2Breast Cancer2Non-small Cell Lung Cancer2Angiosarcoma1Brain Metastases1Breast Cancer Stage IV1Breast Neoplasms1Breast Tumors1Early-stage Breast Cancer1EGFRm Advanced Non-Small Cell Lung Cancer1EGFRm Metastatic Non-Small Cell Lung Cancer1HER2-negative Breast Cancer1HER2-positive Breast Cancer1Hormone Receptor Negative Tumor1Hormone Receptor Positive Tumor1Locally Advanced Breast Cancer1Lung Cancer1Non Small Cell Lung Cancer1NSCLC1Residual Disease1Stage II/III1TNBC - Triple-Negative Breast Cancer1Triple Negative Breast Cancer (TNBC)1Triple Negative Breast Neoplasms1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING5
RECRUITING4
APPROVED_FOR_MARKETING1
WITHDRAWN1
Phase mix
PHASE27
PHASE13
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.